SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-234035
Filing Date
2019-08-29
Accepted
2019-08-29 16:10:19
Documents
13
Period of Report
2019-08-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d794141d8k.htm   iXBRL 8-K 28731
  Complete submission text file 0001193125-19-234035.txt   184799

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20190828.xsd EX-101.SCH 4107
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ctmx-20190828_def.xml EX-101.DEF 13422
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20190828_lab.xml EX-101.LAB 22031
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20190828_pre.xml EX-101.PRE 14326
6 EXTRACTED XBRL INSTANCE DOCUMENT d794141d8k_htm.xml XML 7917
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 191066466
SIC: 2834 Pharmaceutical Preparations